Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging.

MACSima™ multiplexed tissue imaging single-cell analysis spatial analysis workflow tumor immunophenotyping tumor microenvironment (TME)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 08 02 2024
accepted: 29 02 2024
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 3 4 2024
Statut: epublish

Résumé

Deciphering cellular components and the spatial interaction network of the tumor immune microenvironment (TIME) of solid tumors is pivotal for understanding biologically relevant cross-talks and, ultimately, advancing therapies. Multiplexed tissue imaging provides a powerful tool to elucidate spatial complexity in a holistic manner. We established and cross-validated a comprehensive immunophenotyping panel comprising over 121 markers for multiplexed tissue imaging using MACSima™ imaging cyclic staining (MICS) alongside an end-to-end analysis workflow. Applying this panel and workflow to primary cancer tissues, we characterized tumor heterogeneity, investigated potential therapeutical targets, conducted in-depth profiling of cell types and states, sub-phenotyped T cells within the TIME, and scrutinized cellular neighborhoods of diverse T cell subsets. Our findings highlight the advantage of spatial profiling, revealing immunosuppressive molecular signatures of tumor-associated myeloid cells interacting with neighboring exhausted, PD1

Identifiants

pubmed: 38566984
doi: 10.3389/fimmu.2024.1383932
pmc: PMC10985204
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1383932

Informations de copyright

Copyright © 2024 Scheuermann, Kristmann, Engelmann, Nuernbergk, Scheuermann, Koloseus, Abed, Solass and Seitz.

Déclaration de conflit d'intérêts

The authors acknowledge that this work has been initiated as part of a collaborative research agreement with Miltenyi Biotec within our institution functioning as beta testers for the MACSima™ imaging platform. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Sophia Scheuermann (S)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.
iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.
German Cancer Consortium (DKTK), partner site Tuebingen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Tuebingen, Tuebingen, Germany.

Beate Kristmann (B)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.

Fabienne Engelmann (F)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.

Alice Nuernbergk (A)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.

David Scheuermann (D)

School of Business and Economics, Faculty of Economics and Social Sciences, University of Tuebingen, Tuebingen, Germany.

Marie Koloseus (M)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.

Tayeb Abed (T)

Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center, Tuebingen, Germany.

Wiebke Solass (W)

Institute of Tissue Medicine and Pathology (ITMP), University of Bern, Bern, Switzerland.

Christian M Seitz (CM)

Department of Haematology, Oncology, Gastroenterology, Nephrology, Rheumatology, University Children's Hospital Tuebingen, Tuebingen, Germany.
iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tuebingen, Tuebingen, Germany.
German Cancer Consortium (DKTK), partner site Tuebingen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Tuebingen, Tuebingen, Germany.

Classifications MeSH